Illumina, Inc. $ILMN Shares Sold by KLP Kapitalforvaltning AS

Key Points

• KLP Kapitalforvaltning AS trimmed its position in Illumina by 13.1% in Q4, selling 9,100 shares and leaving 60,345 shares valued at $7.915 million; institutional investors own 89.42% of the stock.
• Illumina beat quarterly estimates with $1.35 EPS (vs. $1.26 est.) and $1.16B revenue (vs. $1.10B est.), set FY2026 guidance of 5.050–5.200 EPS, and trades around $127.88 with a $19.43B market cap.
• Analyst coverage is mixed—consensus rating is Hold with an average price target of $129.69, and the poll includes 6 Buys, 10 Holds and 2 Sells.

KLP Kapitalforvaltning AS trimmed its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 60,345 shares of the life sciences company's stock after selling 9,100 shares during the period. KLP Kapitalforvaltning AS's holdings in Illumina were worth $7,915,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Board of the Pension Protection Fund acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC boosted its holdings in shares of Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock worth $26,000 after purchasing an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Quent Capital LLC acquired a new position in shares of Illumina during the 3rd quarter worth approximately $29,000. Finally, Quarry LP acquired a new position in shares of Illumina during the 3rd quarter worth approximately $32,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ILMN shares. Piper Sandler lowered their target price on Illumina from $195.00 to $170.00 and set an "overweight" rating on the stock in a report on Monday, February 9th. Weiss Ratings restated a "hold (c-)" rating on shares of Illumina in a report on Monday, December 29th. JPMorgan Chase & Co. lowered their target price on Illumina from $130.00 to $120.00 and set a "neutral" rating on the stock in a report on Friday, February 6th. Guggenheim boosted their target price on Illumina from $144.00 to $170.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Finally, Evercore set a $150.00 target price on Illumina in a report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $129.69.

Illumina Stock Up 1.9%

ILMN stock opened at $127.88 on Friday. The firm has a market cap of $19.43 billion, a PE ratio of 23.46, a PEG ratio of 2.41 and a beta of 1.49. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The firm's 50 day moving average price is $125.10 and its 200-day moving average price is $125.62. Illumina, Inc. has a one year low of $73.86 and a one year high of $155.53.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.12 EPS for the current year.

Insider Activity at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares of the company's stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.60% of the company's stock.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.